Biotech Values

[mskatiescarletohara]

Good Morning to all...Nicksdad

Regarding the FFB, I would not lose any sleep over GENR's Phase I/II trial not being listed on their website. IMO, the Phase I/II trial was conducted to assess safety, and the big surprise was efficacy. There also may have been some skepticism the trial would fail, also, there are other young clinical candidates out there being tested and they are not getting any support from the FFB. The FFB IMO, will endorse candidates once they are proven in the clinic. Now, why this study's results are not on their website now, I don't know.

What is important, is the FFB has recognized and endorsed Squalamine NOW, if I am not mistaken the doctor representing the FFB was on the CC when the results were announced. I believe once GENR makes their clinical trial strategy moving forward known, then the FFB will give them a window on their website, and perhaps a summary of the Mexico results.

GENR is graduating from a micro-cap preclinical intellectual property to a small-cap company with intellectual property expanding into human trials. I feel the company is on the right track for moving Squalamine into larger clinical studies, by properly presenting the data, hiring a CFO, and aligning themselves with the advocates.

By the way, I know someone attending the R&R conference this week, I hope to get some feedback on some of the folks presenting, and what folks were whispering about GENR!

Regards,

katie....